Mini review: Current status and perspective of S100B protein as a biomarker in daily clinical practice for diagnosis and prognosticating of clinical outcome in patients with neurological diseases with focus on acute brain injury

2023 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Mini review: Current status and perspective of S100B protein as a biomarker in daily clinical practice for diagnosis and prognosticating of clinical outcome in patients with neurological diseases with focus on acute brain injury​
Abboud, T. ; Rohde, V. & Mielke, D.​ (2023) 
BMC Neuroscience24(1).​ DOI: https://doi.org/10.1186/s12868-023-00807-2 

Documents & Media

Main article649.97 kBAdobe PDF

License

Published Version

Attribution 4.0 CC BY 4.0

Details

Authors
Abboud, Tammam ; Rohde, Veit; Mielke, Dorothee
Abstract
Abstract Prognosticating the clinical outcome of neurological diseases is essential to guide treatment and facilitate decision-making. It usually depends on clinical and radiological findings. Biomarkers have been suggested to support this process, as they are deemed objective measures and can express the extent of tissue damage or reflect the degree of inflammation. Some of them are specific, and some are not. Few of them, however, reached the stage of daily application in clinical practice. This mini review covers available applications of the S100B protein in prognosticating clinical outcome in patients with various neurological disorders, particularly in those with traumatic brain injury, spontaneous subarachnoid hemorrhage and ischemic stroke. The aim is to provide an understandable picture of the clinical use of the S100B protein and give a brief overview of the current limitations that require future solutions.
Issue Date
2023
Journal
BMC Neuroscience 
eISSN
1471-2202
Language
English
Sponsor
Open-Access-Publikationsfonds 2023

Reference

Citations


Social Media